Saturday, October 24, 2015

Competitor Analysis Amyloid beta- and Tau-Targeted Antibodies & Vaccines

DUBLIN--(BUSINESS WIRE)--Research and Markets (.researchandmarkets.com/research/hgxqzb/competitor) has announced the addition of the "Competitor Analysis: Amyloid beta- and Tau-Targeted Antibodies & Vaccines" report to their offering. The Competitive Intelligence Report Amyloid beta- and Tau-Targeted Antibodies & Vaccines as of September 2015 provides a competitor analysis in the development pipeline of novel antibodies and vaccines for passive and active immunotherapy of Alzheimer s disease or progressive supranuclear palsy (PSP) by targeting amyloid-beta (beta-amyloid) or tau. About Diamox (Acetazolamide) without prescription Purchase of the downloadable pdf report includes a 6-month online access to the data of the report and any updates since the publication date. Buy Revia (Naltrexone) without Rx Credentials to access the database will be sent by e-mail and allow online work with the project data to print or export an individual report. The report includes a compilation of currently active projects in research and development of novel antibodies and vaccines for amyloid beta- and tau-targeted passive and active imunotherapy of Alzheimer s disease. Buy Zyrtec (Cetirizine) with no prescription In addition, the report lists company-specific R&D pipelines of amyloid beta- and tau-targeted antibodies & vaccines. Competitor projects are listed in a tabular format providing Information on: Drug Codes Target / Mechanism of Action Class of Compound Company Product category/Therapeutic Area Indication R&D Stage Key Topics Covered: 1. Haloperidol with no Rx Amyloid beta-Targeted Antibodies 2. About Detrol (Tolterodine) without prescription Amyloid beta-Targeted Vaccines 3. Buy Fresh Breath online Tau-Targeted Antibodies 4. http://medical-reviews.blogspot.com Tau-Targeted Vaccines 5. Corporate Amyloid beta- and Tau-Targeted Antibodies & Vaccines R&D Portfolios For more information visit .researchandmarkets.com/research/hgxqzb/competitor

No comments:

Post a Comment